Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita ...

Heart disease remains the leading cause of death worldwide, yet progress in understanding and treating cardiac disorders is ...

Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita Therapeutics that has the potential to prevent and reverse liver fibrosis — a ...

Mechanical cues are key regulators of cardiac development, yet their role in organoid maturation remains underexplored. In a ...

Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita Therapeutics that has the ...

Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita ...

Heart disease remains the leading cause of death worldwide, yet progress in understanding and treating cardiac disorders is limited by the ...

Chevy Chase revealed that he had a near-fatal heart failure that led to a coma and severe memory loss in 2021 in the CNN ...

Centre bans manufacture, sale and distribution of oral nimesulide doses above 100 mg nationwide, citing liver toxicity risks ...

The year saw the emergence of a new version of an old drug that proved beneficial in patients who have heart failure with reduced ejection fraction (HFrEF) and the approval of a new nonsteroidal ...

The average duration of weight-loss treatment was 39 weeks, with an average follow-up of 32 weeks. Participants treated with ...

Heart disease remains the leading cause of death worldwide, yet progress in understanding and treating cardiac disorders is limited by the shortcomings of existing experimental models. Traditional ...